Date:2/16/2010

2009 2008 ---- ---- Cash flows from operating activities: Net loss $(35,858,846) $(51,064,241) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 441,809 530,805 Employee and non-employee stock-based compensation 11,230,227 13,387,789 Loss on disposal of assets - (174) Amortization of discounts and premiums on marketable securities 138,095 (235,162) Amortization of intangible assets 982,935 - Changes in assets and liabilities: Prepaid expenses and other current assets (805,181) 495,200 Accounts receivable (3,163,898) - Deposits - 150,000 Inventory (2,398,517) - Accounts payable 1,911,495 (2,475,697) Accrued expenses (577,116) (6,892,577) Deferred rent 4,082 148,728 Deferred revenue 197,431,193 - ----------- ------- Net cash provided by (used in) operating activities 169,336,278 (45,955,329) ----------- ----------- Cash flow
'/>"/>

SOURCE Vanda Pharmaceuticals Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results